Vera Therapeutics Clinical Trial Data
Vera Therapeutics announced positive topline results from the final efficacy analysis of its Phase 3 ORIGIN 3 trial of TRUTAKNA (atacicept-vymj) in patients with IgA nephropathy. The trial met all prespecified endpoints, demonstrating a 76% reduction in the risk of kidney disease progression and stabilization of kidney function (eGFR) through 104 weeks. The company plans to submit a supplemental BLA for full FDA approval in the fourth quarter of 2026.
- Term
- 104 weeks